- HCV treatment with direct-acting antivirals (DAAs) is safe and effective in liver transplant (LT), kidney transplant (KT), and dual liver kidney (DLK) transplant recipients.
Why this matters
- Real-world cohorts reflect a more diverse population than clinical trials.
You’ve reached the visitor articles limit
reserved for healthcare professionals
Register to read more
Already have an account? Login now